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Figure 1. Comparison between the performance of 
radiochromic film and PUMA for analysis of motion effects on 
low modulated SABR lung plans 
Conclusions: PUMA can predict the interplay effect on SABR 
lung cancer patients and has the potential to be used as a 
routine method to ensure an appropriate low level of 
modulation on SABR lung plans independently of the energy. 
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Preclinical evaluation of novel anticancer agents combined to 
Ionizing Radiation (IR) is a key step in the generation of a 
sound rationale for further transfer towards the early clinical 
phases. Animal models should allow the minimal assessment 
of the toxicity hazard and provide significant signs of 
increased anti tumor efficacy, both required to address their 
clinical relevance, i.e. the therapeutic ratio of a candidate 
future combination. 
This assumption is clearly challenged by the major 
discrepancy between the amount of combinations suggested 
by preclinical data in the last decade and the fact that 
platinum based combinations remain the mostly widely used 
agents in the management of lung tumors. This not only 
illustrates the difficulties in funding the continuum from 
promising preclinical data to clinical steps, but also 
underscores the relatively low relevance of our preclinical 
models. Certainly, one of the reasons for this gap is the 
inhabitility of our preclinical models to keep up with the 
changes in the mutational landscape of lung cancer. Another 
major aspect is that most models used so far include 
immunocompromised models, which fail to recapitulate the 
importance of the tumor stroma in the processes of radiation 
response. The precise correlation between the preclinical 
judgment criteria and the medical need is also key : while 
most preclinical papers focus on tumor growth delays, the 
clinical need is to increase local control and to minimize the 
onset of metastasis. Lastly, the potential deleterious impact 
on normal tissues, both acute and long term, should also be 
properly evaluated at the preclinical stage to increase the 
accuracy of this appraisal. Preclinical models should also try 
to address the current challenges of the biomarker era and 
suggest in which biological context, and which criteria may 
be used to define the optimal biological context for patient 
selection. Importantly, integration of cisplatinum based 
chemotherapy as a reference may be useful for proper 
assessment of potential clinical gains. To conclude, 
immunological and vascular parameters can be dramatically 
affected by fractionation, fractionating irradiation is thus 
important for the evaluation of candidate combinations. 
Genetically engineered mice models and orthotopic murine 
models in immunocompetent recipient mice should markedly 
contribute to an improvement of the output of these murine 
models and eventually increase the success rates of future 
clinical trials while avoiding the transfer of uneffective or 
hazardous combinations to the patient. 
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Non-small cell lung cancer (NSCLC) is a group of different 
histologic tumor types with diverse molecular aberrations.  
Lung adenocarcinomas are now classified according to driving 
molecular abnormalities (mutations, rearrangements or 
amplifications), which can be identified in more than half of 
tumors, leading to effective systemic therapies in many of 
these patients. In contrast to that, evidence for presence of 
such abnormalities in squamous cell lung carcinomas is less 
clear. Successful combination of targeted therapies, 
chemotherapy and radiation in early NSCLC should be taken 
into account in the context of molecular drivers. In 
oncogenic-driven stage III NSCLC, it is likely that effective 
systemic treatment will be combined with radical 
radiotherapy or radiochemotherapy as a sequential 
 treatment, although evidence for such approach is currently 
lacking. RTOG 1306 phase II clinical trial is currently 
randomly allocating stage III patients with tumors showing 
EGFR mutations or ALK rearrangements to either 
radiochemotherapy alone (control group) or 12 weeks of 
erlotinib (EGFR cohort) or crizotinib (ALK cohort) followed by 
definitive radiochemotherapy. In non-oncogene addicted 
NSCLC, incorporation of targeted therapies into 
radiochemotherapy schedules is very difficult to predict 
preclinically, as demonstrated by several examples, including 
negative results of the RTOG 0617 trial. This trial failed to 
show any benefit from the addition of cetuximab, a 
monoclonal antibody targeting EGFR, into radiochemotherapy 
in stage III NSCLC. Lack of good prediction of clinical data 
may result from complex interactions among targeted agents, 
chemotherapy, and radiation. One of the most promising 
strategies for the future is related to the success of immune 
checkpoint inhibitors, which show considerable promise as 
adjuvant systemic treatment after definitive 
radiochemotherapy.  
Optimization of combined radiation and chemotherapy 
programs is still a matter of ongoing discussions and 
investigations. Although concurrent radiochemotherapy is a 
standard of care in fit stage III NSCLC patients, sequential 
treatments with cytotoxic agents followed by either 
hypofractionated or hyperfractionated accelerated 
radiotherapy schedules are currently revisited.  
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Purpose/Objective: IDEAL-CRT and I-START are phase I/II 
trials investigating isotoxic dose escalation in patients with 
stage IIa-IIIb non-small cell lung cancer. In both trials the 
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prescription dose was escalated to the maximum level 
achievable for each patient according to predefined organs at 
risk (OAR) toxicity and dose constraints. Radiobiological 
models were used to predict a patient-specific radiotherapy 
(RT) dose associated with a 10% risk of grade 3 and above 
pneumonitis which was then constrained to a prescription 
dose of 63-73 Gy in 30# for IDEAL-CRT (plus concurrent 
chemotherapy) and 55-65 Gy in 20# for I-START. These are 
the first multi-centre trials in the UK to investigate isotoxic 
dose escalation and as such incorporated a thorough Quality 
Assurance (QA) programme to ensure protocol compliance. 
Materials and Methods: RT plans were produced across 8 
centres for IDEAL and 12 centres for I-START. Full 3D RT 
planning data was submitted to a central QA contact. All RT 
plans and plan assessment forms were analysed for quality 
and protocol compliance. 
Results: Between 2010 and 2014, 84 and 81 patients were 
recruited to IDEAL-CRT and I-START respectively. Table 1 
shows the average doses received by OAR and targets 




Patients not reaching the suggested CTV and PTV dose 
coverage were not considered protocol deviations as this was 
a recommendation only.  
2/84 IDEAL-CRT patients exceeded 1 or more of the Lungs-
GTV dose limits and 1 patient exceeded the brachial plexus 
dose to 0.1cc. 2/81 I-START patients exceeded the spinal 
cord dose tolerance quoted in V1.0 of the protocol. Brachial 
plexus dose deviations were seen in 3 I-START patients with 2 
patients exceeding the tolerance dose stated in V1.0 and 1 
patient exceeding the dose in V2.0 of the trial protocol. The 
initial cautious dose constraints stated in V1.0 of the I-START 
protocol were modified in V2.0 to reflect standard clinical 
practice and achieve consistency with IDEAL-CRT. No 
protocol deviations were seen in the dose to the heart and 
oesophagus in both trials. 
Conclusions: Protocol deviations for IDEAL-CRT and I-START 
were seen in less than 4% and 6% of patients respectively. 
Complex dose escalation trials can be carried out in a 
multicentre setting provided there is a comprehensive pre-
trial and on-trial QA programme in place.  
IDEAL-CRT (C13530/A17007) and ISTART (C25518/A11535) are 
funded by Cancer Research UK. 
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Purpose/Objective: Concurrent chemo-radiation (CRT) is the 
treatment of choice for local advanced NSCLC patients. 
Despite the curative intent of the treatment, survival is poor 
with a median survival of about 16-18 months (m) and a 5 
year (y) survival of 15%. The loco-regional control rate at 2 y 
is only about 30% in clinical trials. This randomized phase-II 
trial tested a dose intense oral vinorelbine (Nav) regimen 
with two doses of RT, 60 Gy/30 F (arm A) and 66 Gy/33 F 
(arm B). 
Materials and Methods: Before randomization to arm A or B, 
the patients were treated with 2 cycles of induction 
chemotherapy (Carboplatin+Nav). In both arms, Nav was 
given as concurrent chemotherapy (a fixed dose of 50 mg 
3/week for the full course of CRT). Follow-up CT-scans were 
performed every 3 m starting 1 m after commencing 
radiotherapy for 2 y and then every 6 m. As part of the 
protocol, a PET-CT scan was conducted 9 m after 
randomization.  
The primary endpoint was the Local Progression Free Survival 
Rate (LPFSR). The goal of the study was within the 95% 
confidence interval (95%CI) to have a LPFSR at 9 m of 80%. 
Log rank tests were used to test survival. 
Results: In arm A and B, 59 and 58 patients were eligible. 
The two arms were well balanced. The minimum and median 
potential follow-up was 14.5 and 32.6 m, respectively. The 
median number of Nav was 18 x in arm A and 20 x in arm B. 
Of the patients, 10% had ≤12 x Nav. The LPFSR at 9 m was in 
arm A: 54% (95%CI: 43%; 64%), and in arm B: 60% (95% CI: 
49%; 71%), and the LPFSR at 1 and 2 year was 40% and 32% in 
arm A, and 49% and 44%, in arm B. The median LPFSR was 
10.0 m and 10.9 m in arm A and B (p=0.57). The median OS 
was 23.3 m in arm A, and 25.3 m in arm B. The 1 and 2 y 
overall survival was 83% and 46% in arm A, and 81% and 51% 
in arm B (p=0.67). This was similar to the survival in a 
comparable reference group. 
Side effects: Hematological Grade (G) 4 side effects were 
observed in 2 patients in each arm. Dysphagia and dyspnoe 
tended to be higher in arm B. One G4 pneumonitis was 
observed in arm A and 1 G5 in arm B. Mean weight loss was 
2.8% in arm A, and of 1.5% in arm B. The difference was not 
statistically significant. Weight loss of 10-20% was observed in 
7% and 3% of the patients in arm A and B, respectively; but 
no one had a G3 weight loss (≥20%). A late effect esophageal 
stricture/ulceration G3 or more occurred in 3 (5%) of the 
patients in arm A and 4 (7%) in arm B, and one of these in 
arm B was a G5 fistula at the site of the primary tumor.  
Conclusions: The phase II goal was not met in neither of the 
treatment arms. This may be caused by the extensive use of 
PET-CT scan in the study revealing progressions earlier than 
was expected from previous studies, or it could have been 
caused by the omission of concurrent cisplatin. The survival 
of the two arms was however comparable. Since both 
treatment arms were well tolerated with no differences in 
toxicity between the arms, and the 66 Gy arm had a trend to 
better loco-regional control, we have chosen this treatment 
arm (with cisplatin added) as the reference arm in a phase III 
